Silence Therapeutics plc (SLN) Form 8-K — Oct 19, 2026
Silence Therapeutics has agreed to be acquired by Merck KGaA in an all-cash deal at $6.6667 per ordinary share, or $20.00 per American Depositary Share, via a UK scheme of arrangement. The deal was announced October 19, 2026 and is recommended by the company's board. The transaction requires 75% shareholder approval, antitrust clearances in the US and Germany, and UK High Court sanction, with an outside date of April 30, 2027. Holders of roughly 14% of voting power have already signed voting support agreements, and there is no financing condition.
Key figures
- Offering Price
- 20
- End date
- 2027-04-30
- Ads outstanding
- 61947666
- Termination fee usd
- 13000000
- Ordinary shares issued
- 186609072
- Voting support percent
- 14
- Per share consideration usd
- 6.6667
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.